Brief: Poxel 9-Month Revenue Down At EUR 286 Thousand

Poxel SA

08/11/2022 16:58

Nov 8 (Reuters) - Poxel SA  POXEL.PA :
    * POXEL PROVIDES CORPORATE UPDATE AND REPORTS CASH AND
REVENUE FOR
THE THIRD QUARTER AND NINE MONTHS 2022
    * EXTENSION OF CASH RUNWAY THROUGH AT LEAST FEBRUARY 2023
    * AS OF SEPTEMBER 30, 2022, CASH AND CASH EQUIVALENTS WERE
EUR
17.1 MILLION (USD 16.6 MILLION)
    * PHASE 2 NASH TRIAL (DESTINY-1) FOR PXL065 MET ITS PRIMARY
EFFICACY ENDPOINT FOR LIVER FAT CONTENT REDUCTION AT 36 WEEKS
FOR ALL DOSES
    * PXL065 PRIORITIZED FOR FURTHER DEVELOPMENT IN NASH BASED
ON
POSITIVE RESULTS FROM DESTINY-1 TRIAL
    * PXL770 DEVELOPMENT TO FOCUS EXCLUSIVELY ON RARE DISEASES,
DRIVEN
BY PROMISING DATA WHICH SHOWED STRONG POTENTIAL IN MULTIPLE RARE
METABOLIC INDICATIONS
    * 9-MONTH REVENUES EUR 286 THOUSAND VS 13,274 THOUSAND YEAR
AGO 

Source text for Eikon:  ID:nBwflBNVa 
Further company coverage:  POXEL.PA 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))